Names of Reporting Persons.
Conan Laughlin 10.6% (10.9% as of December 31, 2014)
** Shares reported herein for North Tide Capital, LLC (“North Tide”) represent shares which are beneficially owned by North Tide Capital Master, LP (the “Master Fund”), as reported herein, and shares which are beneficially owned by a managed account (the “Account”). North Tide serves as investment manager to both the Master Fund and the Account. Shares reported herein for Mr. Laughlin represent the above referenced shares beneficially owned by the Master Fund and the Account. Mr. Laughlin serves as the Manager of North Tide. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.
Adam Feuerstein's Biotech Blog - TheStreet
Regulators Want Drug Companies to Be Honest About FDA ... Obese Americans taking Contrave to lose weight cut their risk of having a heart attack, stroke or dying from ... is unknown, according to a review of the inhaled insulin published this week by The Medical Letter.
VVUS getting ready after much of resistance at 3 ...break anytime soon as 1mil shares already short today
Vivus' Qsymia Breaks 3-Week Stagnancy, Could Start Upward Trend
Mar. 16, 2015 9:51 AM ET | 3 comments | About: Vivus, Inc. (VVUS), Includes: ARNA, OREX
Disclosure: The author is long ARNA, OREX. (More...)
Qsymia breached 11,000 total prescriptions for the first time in 2015, its highest total in 10 months.
The performance was also surprisingly the best of the week compared to two rival products.
March has historically been a month of weekly growth.
DUBLIN, March 16, 2015 /PRNewswire/ --
•Company Focused on Moving Forward with its Growth Strategies and Active Pipeline of Acquisition Targets
Endo International plc (NASDAQ: ENDP) (TSX: ENL) today confirmed that it is withdrawing its cash and stock proposal to acquire Salix Pharmaceuticals, Ltd. Endo is moving forward with its growth strategies and active pipeline of acquisition targets across its three core platforms – U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals.
Endo issued the following statement:
"While we are disappointed with this outcome, we have been and will continue to be disciplined in our approach to potential acquisitions. We would like to wish Salix and Valeant continued success as they move forward with their transaction. As a next step, Endo is focusing our attention on other opportunities in our robust deal pipeline and on maximizing our organic growth initiatives including progressing our R&D pipeline. We will continue to drive Endo's growth as a global leader in specialty pharmaceuticals and look forward to creating value for our shareholders while improving patients' lives."
The FDA also has required post-marketing safety studies for most of the drugs and monitors real-world use for safety signals.
Ronald Sha, medical director at Duke University’s Diet and Fitness Center, says he has waited for up to a year after each new diet drug has come out before prescribing it, to allow for unforeseen safety issues that might emerge. He says he now feels comfortable prescribing Qsymia, which was approved by the FDA in 2012.
At first, Ms. Schulz was skeptical of Qsymia, because she was aware of the safety problems with older diet drugs. “I was fearful this could make things worse,” she says.
She carefully read the extensive medication insert that outlines the known safety risks for Qsymia, and she researched the drug online. A big safety issue for Qsymia is that pregnant women shouldn’t take it because it can cause cleft lips in fetuses. That didn’t concern her, she says, because she is past child-bearing age.
Ms. Schulz began taking the drug, in addition to modifying her diet and exercise and has dropped about 25 pounds since the fall. She says Qsymia makes her feel less hungry.